153 related articles for article (PubMed ID: 9840302)
1. Effect of subcutaneous injection of granulocyte-macrophage colony stimulating factor (GM-CSF) on healing of chronic refractory wounds.
Malik IA; Zahid M; Haq S; Syed S; Moid I; Waheed I
Eur J Surg; 1998 Oct; 164(10):737-44. PubMed ID: 9840302
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human GM-CSF in the treatment of poorly healing wounds.
Groves RW; Schmidt-Lucke JA
Adv Skin Wound Care; 2000; 13(3 Pt 1):107-12. PubMed ID: 11075003
[TBL] [Abstract][Full Text] [Related]
3. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
4. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
Small EJ; Reese DM; Um B; Whisenant S; Dixon SC; Figg WD
Clin Cancer Res; 1999 Jul; 5(7):1738-44. PubMed ID: 10430077
[TBL] [Abstract][Full Text] [Related]
5. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
[TBL] [Abstract][Full Text] [Related]
6. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
7. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma.
Lendemans S; Kreuzfelder E; Waydhas C; Schade FU; Flohé S
Inflamm Res; 2007 Jan; 56(1):38-44. PubMed ID: 17334669
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human granulocyte-macrophage colony-stimulating factor as treatment for chronic leg ulcers.
Borbolla-Escoboza JR; María-Aceves R; López-Hernández MA; Collados-Larumbe MT
Rev Invest Clin; 1997; 49(6):449-51. PubMed ID: 9528304
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
Dinçol D; Samur M; Pamir A; Sencan O; Akbulut H; Yalçin B; Onur H; Demirkazik A; Senler FC; Içli F
Cancer; 2000 May; 88(9):2033-6. PubMed ID: 10813713
[TBL] [Abstract][Full Text] [Related]
10. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.
Ryu JK; Swann S; LeVeque F; Scarantino CW; Johnson D; Chen A; Fortin A; Pollock J; Kim H; Ang KK
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):643-50. PubMed ID: 17293228
[TBL] [Abstract][Full Text] [Related]
11. [Effect of granulocyte-macrophage colony-stimulating factor on the mammalian target of sirolimus signaling pathway in the wound of rat].
Cui WH; Huang H; Xu X; Guo M; Dai H; Jian Y; Guo W; Xing W; Jiang JX; Yang R
Zhonghua Shao Shang Za Zhi; 2012 Feb; 28(1):36-41. PubMed ID: 22490538
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of subcutaneous-only granulocyte-macrophage colony-stimulating factor for collateral growth promotion in patients with coronary artery disease.
Zbinden S; Zbinden R; Meier P; Windecker S; Seiler C
J Am Coll Cardiol; 2005 Nov; 46(9):1636-42. PubMed ID: 16256861
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic wounds by local delivery of granulocyte-macrophage colony-stimulating factor in patients with neutrophil dysfunction.
De Ugarte DA; Roberts RL; Lerdluedeeporn P; Stiehm ER; Atkinson JB
Pediatr Surg Int; 2002 Sep; 18(5-6):517-20. PubMed ID: 12415398
[TBL] [Abstract][Full Text] [Related]
16. Locally applied granulocyte-macrophage colony-stimulating factor improves the impaired bowel anastomoses in rats with long-term corticosteroid treatment.
Dinc S; Alagol H; Gulcelik MA; Ozbirecikli B; Kuru B; Renda N; Ustun H
World J Surg; 2002 Oct; 26(10):1208-13. PubMed ID: 12205560
[TBL] [Abstract][Full Text] [Related]
17. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
18. Practical Application of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Patients with Wounds.
Brem H; Howell R; Criscitelli T; Senderowicz A; Siegart N; Gorenstein S; Gillette B
Surg Technol Int; 2018 Jun; 32():61-66. PubMed ID: 29611156
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
Ryan CJ; Weinberg V; Rosenberg J; Fong L; Lin A; Kim J; Small EJ
J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
[TBL] [Abstract][Full Text] [Related]
20. The effects of locally injected granulocyte macrophage-colony stimulating factor on the healing of intraoperatively irradiated intestinal anastomoses in rats.
Dinc S; Ozbirecikli B; Gulcelik MA; Ergeneci D; Kuru B; Erdem E; Caydere M; Alagol H
J Exp Clin Cancer Res; 2004 Mar; 23(1):77-82. PubMed ID: 15149154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
